A Phase 1/2 interventional study of ARQ-151 cream 0.5% and ARQ-151 cream 0.15% in Psoriasis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-04.
Sponsored by Arcutis Biotherapeutics, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing roflumilast in Psoriasis — 3 open to participants now, 3 under way, none of them phase 3. Roflumilast · Psoriasis.
Among the 17 studies testing roflumilast in Psoriasis, this one is the 8th largest by enrollment, is the only one that started in 2017, is the only one in phase 1/2, and was the 2nd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →3 of the 17 studies testing roflumilast in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:
Modern Research Associates, PLLC · Sites in United States
Ahmed Ibrahim · Sites in Egypt
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 6 · Phase 4 2
First in 2008; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 91 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 46 across the 17 interventional studies. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 9 most frequent:
Arcutis Biotherapeutics, Inc. is the lead sponsor of 26 studies on the registry; 2 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 20 (83%) have results posted.
12 studies in Psoriasis by Arcutis Biotherapeutics, Inc.: none open now, none under way, none of them phase 3. Of 12 finished, 10 (83%) have results posted.
Among the 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc., this one is the 8th largest by enrollment, is the only one that started in 2017, is the only one in phase 1/2, and was the 1st registered.
Arcutis Biotherapeutics, Inc.’s Psoriasis studies by the year they started, since 2017.
1 of the studies testing roflumilast in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07725822Modern Research Associates, PLLCAn Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail Psoriasis | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing roflumilast in Psoriasis, from their registry updates:
Among Arcutis Biotherapeutics, Inc.’s 12 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study assessed the safety and pharmacokinetics (PK) of a single dose application of ARQ-151 cream 0.5% to 25 cm\^2 of psoriatic plaque(s) (Cohort 1). The study also assessed the safety, PK and efficacy of ARQ-151 cream 0.5% vs vehicle and ARQ-151 cream 0.15% vs vehicle applied once a day for 28 days to individuals with 0.5% to 5.0% body surface area (BSA) of chronic plaque psoriasis (Cohort 2).
There were 2 cohorts of participants. Cohort 1 was a single dose study of ARQ-151 0.5% cream applied to 25 cm\^2 of psoriatic plaque(s) in 8 psoriasis participants. Cohort 2 was a parallel group, double blind, vehicle controlled study in which ARQ-151 cream 0.5%, ARQ-151 cream 0.15% or vehicle cream was applied once a day for 28 days to participants with between 0.5% to 5.0% BSA of chronic plaque psoriasis. Participants were adult (≥18 years old) males or females with chronic plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single-dose application of ARQ-151 cream 0.5% to 25 cm\^2 of psoriatic plaque(s)
Drug: ARQ-151 cream 0.5%
ARQ-151 cream 0.5% applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
Drug: ARQ-151 cream 0.5%
ARQ-151 cream 0.15% applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
Drug: ARQ-151 cream 0.15%
Vehicle cream applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
Drug: ARQ-151 vehicle cream
0.5% active concentration
0.15% active concentration
Vehicle cream
Percent Change From Baseline in 4 Week Target Plaque Severity Score x Target Plaque Area in Cohort 2
Difference in least squares mean percent change from baseline at Week 4 in the product of target plaque severity score (TPSS) x target plaque area (TPA) between each dose concentration level of ARQ-151 cream and vehicle using mixed model repeated measures (MMRM) analysis with center within country, treatment, study visit, and treatment-by-study visit interaction as fixed effects and baseline TPSS x TPA score as a covariate. For TPSS, all target lesions were scored individually for signs of induration, scaling, and erythema using a 5-point severity scale: 0 = none; 1 = mild; 2 = moderate; 3 = severe; 4 = very severe. TPA (cm\^2) was determined by multiplying the longest diameter (cm) of the target plaque by the widest perpendicular diameter (cm) (perpendicular to the longest diameter of the target plaque). A negative percent change indicates improvement.
Time frame: Baseline and Week 4
Percent Change From Baseline in 1, 2, 3 Week Target Plaque Severity Score x Target Plaque Area in Cohort 2
Difference in least squares mean percent change from baseline at Weeks 1, 2 and 3 in target plaque severity score (TPSS) x target plaque area (TPA) between each dose concentration level of ARQ-151 cream and vehicle using mixed model repeated measures (MMRM) analysis with center within country, treatment, study visit, and treatment-by-study visit interaction as fixed effects and baseline TPSS x TPA score as a covariate. For TPSS, all target lesions were scored individually for signs of induration, scaling, and erythema using a 5-point severity scale: 0 = none; 1 = mild; 2 = moderate; 3 = severe; 4 = very severe. TPA (cm\^2) was determined by multiplying the longest diameter (cm) of the target plaque by the widest perpendicular diameter (cm) (perpendicular to the longest diameter of the target plaque). A negative percent change indicates improvement.
Time frame: Baseline and Weeks 1, 2 and 3
Percent Change From Baseline in Total Plaque Severity Score in Cohort 2
Difference in least squares mean percent change from baseline at Weeks 1, 2, 3 and 4 in total plaque severity score (TPSS) between each dose concentration level of ARQ-151 cream and vehicle using mixed model repeated measures (MMRM) analysis with center within country, treatment, study visit, and treatment-by-study visit interaction as fixed effects and baseline TPSS score as a covariate. For TPSS, all target lesions were scored individually for signs of induration, scaling, and erythema using a 5-point severity scale: 0 = none; 1 = mild; 2 = moderate; 3 = severe; 4 = very severe. A negative percent change indicates improvement.
Time frame: Baseline and Weeks 1, 2, 3, and 4
Percent Change From Baseline in Target Plaque Area in Cohort 2
Difference in least squares mean percent change from baseline at Weeks 1, 2, 3, and 4 in target plaque area (TPA) between each dose concentration level of ARQ-151 cream and vehicle using mixed model repeated measures (MMRM) analysis with center within country, treatment, study visit, and treatment-by-study visit interaction as fixed effects and baseline TPA score as a covariate. Target plaque area (cm\^2) was determined by multiplying the longest diameter (cm) of the target plaque by the widest perpendicular diameter (cm) (perpendicular to the longest diameter of the target plaque). A negative percent change indicates improvement.
Time frame: Baseline and Weeks 1, 2, 3, and 4
The study was conducted in 7 centers in Canada and 1 center in the United States (US). There was a total of 91 unique participants; 6 participants who completed Cohort 1 also participated in Cohort 2, with 2 per treatment group.
| Milestone | Cohort 1 - ARQ-151 Cream 0.5% | Cohort 2 - ARQ-151 Cream 0.5% | Cohort 2 - ARQ-151 Cream 0.15% | Cohort 2 - ARQ-151 Vehicle Cream |
|---|---|---|---|---|
| Started | 8 | 0 | 0 | 0 |
| Completed | 8 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1 - ARQ-151 Cream 0.5% | Cohort 2 - ARQ-151 Cream 0.5% | Cohort 2 - ARQ-151 Cream 0.15% | Cohort 2 - ARQ-151 Vehicle Cream |
|---|---|---|---|---|
| Started | 0 | 30 | 28 | 31 |
| Completed | 0 | 28 | 27 | 30 |
| Not completed | 0 | 2 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 1 |
| Withdrew: Other | 0 | 1 | 0 | 0 |
Difference in least squares mean percent change from baseline at Week 4 in the product of target plaque severity score (TPSS) x target plaque area (TPA) between each dose concentration level of ARQ-151 cream and vehicle using mixed model repeated measures (MMRM) analysis with center within country, treatment, study visit, and treatment-by-study visit interaction as fixed effects and baseline TPSS x TPA score as a covariate. For TPSS, all target lesions were scored individually for signs of induration, scaling, and erythema using a 5-point severity scale: 0 = none; 1 = mild; 2 = moderate; 3 = severe; 4 = very severe. TPA (cm\^2) was determined by multiplying the longest diameter (cm) of the target plaque by the widest perpendicular diameter (cm) (perpendicular to the longest diameter of the target plaque). A negative percent change indicates improvement.
| Percent change | Cohort 2 - ARQ-151 Cream 0.5% | Cohort 2 - ARQ-151 Cream 0.15% | Cohort 2 - ARQ-151 Vehicle Cream |
|---|---|---|---|
| Percent Change From Baseline in 4 Week Target Plaque Severity Score x Target Plaque Area in Cohort 2 | -66.6 ± 7.27 | -66.0 ± 7.61 | -38.1 ± 7.34 |
Difference in least squares mean percent change from baseline at Weeks 1, 2 and 3 in target plaque severity score (TPSS) x target plaque area (TPA) between each dose concentration level of ARQ-151 cream and vehicle using mixed model repeated measures (MMRM) analysis with center within country, treatment, study visit, and treatment-by-study visit interaction as fixed effects and baseline TPSS x TPA score as a covariate. For TPSS, all target lesions were scored individually for signs of induration, scaling, and erythema using a 5-point severity scale: 0 = none; 1 = mild; 2 = moderate; 3 = severe; 4 = very severe. TPA (cm\^2) was determined by multiplying the longest diameter (cm) of the target plaque by the widest perpendicular diameter (cm) (perpendicular to the longest diameter of the target plaque). A negative percent change indicates improvement.
| Percent change | Cohort 2 - ARQ-151 Cream 0.5% | Cohort 2 - ARQ-151 Cream 0.15% | Cohort 2 - ARQ-151 Vehicle Cream |
|---|---|---|---|
| Week 1 | -34.7 ± 5.79 | -36.4 ± 6.16 | -31.5 ± 5.99 |
| Week 2 | -48.7 ± 6.40 | -50.1 ± 6.75 | -30.4 ± 6.55 |
| Week 3 | -61.5 ± 6.69 | -55.6 ± 7.03 | -32.6 ± 6.81 |
Difference in least squares mean percent change from baseline at Weeks 1, 2, 3 and 4 in total plaque severity score (TPSS) between each dose concentration level of ARQ-151 cream and vehicle using mixed model repeated measures (MMRM) analysis with center within country, treatment, study visit, and treatment-by-study visit interaction as fixed effects and baseline TPSS score as a covariate. For TPSS, all target lesions were scored individually for signs of induration, scaling, and erythema using a 5-point severity scale: 0 = none; 1 = mild; 2 = moderate; 3 = severe; 4 = very severe. A negative percent change indicates improvement.
| Percent change | Cohort 2 - ARQ-151 Cream 0.5% | Cohort 2 - ARQ-151 Cream 0.15% | Cohort 2 - ARQ-151 Vehicle Cream |
|---|---|---|---|
| Week 1 | -30.5 ± 4.96 | -34.3 ± 5.20 | -26.2 ± 5.16 |
| Week 2 | -41.9 ± 5.01 | -45.6 ± 5.22 | -26.4 ± 5.19 |
| Week 3 | -51.5 ± 5.46 | -52.0 ± 5.63 | -30.1 ± 5.56 |
| Week 4 | -55.1 ± 5.41 | -58.2 ± 5.56 | -36.5 ± 5.50 |
Difference in least squares mean percent change from baseline at Weeks 1, 2, 3, and 4 in target plaque area (TPA) between each dose concentration level of ARQ-151 cream and vehicle using mixed model repeated measures (MMRM) analysis with center within country, treatment, study visit, and treatment-by-study visit interaction as fixed effects and baseline TPA score as a covariate. Target plaque area (cm\^2) was determined by multiplying the longest diameter (cm) of the target plaque by the widest perpendicular diameter (cm) (perpendicular to the longest diameter of the target plaque). A negative percent change indicates improvement.
| Percent change | Cohort 2 - ARQ-151 Cream 0.5% | Cohort 2 - ARQ-151 Cream 0.15% | Cohort 2 - ARQ-151 Vehicle Cream |
|---|---|---|---|
| Week 1 | -9.15 ± 2.981 | -8.22 ± 3.198 | -11.82 ± 3.089 |
| Week 2 | -14.95 ± 4.211 | -16.19 ± 4.407 | -10.37 ± 4.225 |
| Week 3 | -22.63 ± 4.666 | -17.00 ± 4.844 | -9.95 ± 4.636 |
| Week 4 | -31.87 ± 6.014 | -28.28 ± 6.228 | -11.61 ± 5.938 |
Collected over Up to approximately 5 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 - ARQ-151 Cream 0.5% | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Cohort 2 - ARQ-151 Cream 0.5% | 0/30 (0%) | 0/30 (0%) | 9/30 (30%) |
| Cohort 2 - ARQ-151 Cream 0.15% | 0/28 (0%) | 0/28 (0%) | 5/28 (17.9%) |
| Cohort 2 - ARQ-151 Vehicle Cream | 0/31 (0%) | 0/31 (0%) | 11/31 (35.5%) |
| Event | Cohort 1 - ARQ-151 Cream 0.5% | Cohort 2 - ARQ-151 Cream 0.5% | Cohort 2 - ARQ-151 Cream 0.15% | Cohort 2 - ARQ-151 Vehicle Cream |
|---|---|---|---|---|
| Application site painGeneral disorders | 0/8 | 2/30 | 1/28 | 5/31 |
| Application site erythemaGeneral disorders | 0/8 | 4/30 | 1/28 | 4/31 |
| CandiduriaInfections and infestations | 1/8 | 0/30 | 0/28 | 0/31 |
| NasopharyngitisInfections and infestations | 0/8 | 2/30 | 2/28 | 0/31 |
| InfluenzaInfections and infestations | 0/8 | 0/30 | 0/28 | 2/31 |
| Muscle strainInjury, poisoning and procedural complications | 0/8 | 1/30 | 1/28 | 2/31 |
Baseline characteristics for Cohort 2 arms are shown for participants who were not in Cohort 1.
| Age, Continuous(Years) | Cohort 1 - ARQ-151 Cream 0.5% | Cohort 2 - ARQ-151 Cream 0.5% | Cohort 2 - ARQ-151 Cream 0.15% | Cohort 2 - ARQ-151 Vehicle Cream | Total |
|---|---|---|---|---|---|
| Mean | 51.6 ± 16.92 | 50.8 ± 15.76 | 54.8 ± 13.50 | 47.0 ± 13.97 | 50.80 ± 14.75 |
| Sex: Female, Male(Participants) | Cohort 1 - ARQ-151 Cream 0.5% | Cohort 2 - ARQ-151 Cream 0.5% | Cohort 2 - ARQ-151 Cream 0.15% | Cohort 2 - ARQ-151 Vehicle Cream | Total |
|---|---|---|---|---|---|
| Female | 7 | 12 | 7 | 12 | 38 |
| Male | 1 | 16 | 19 | 17 | 53 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 - ARQ-151 Cream 0.5% | Cohort 2 - ARQ-151 Cream 0.5% | Cohort 2 - ARQ-151 Cream 0.15% | Cohort 2 - ARQ-151 Vehicle Cream | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 8 | 27 | 26 | 29 | 90 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1 - ARQ-151 Cream 0.5% | Cohort 2 - ARQ-151 Cream 0.5% | Cohort 2 - ARQ-151 Cream 0.15% | Cohort 2 - ARQ-151 Vehicle Cream | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 2 | 2 | 8 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 2 | 0 | 4 |
| White | 8 | 23 | 22 | 20 | 73 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2017 to primary completion in May 2018, 4 months.
Results were first posted in Jul 2021, 3 years 2 months after primary completion. A results delay was requested in Mar 2020.
Of 15 phase 1/2 interventional studies under Psoriasis, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roflumilast
Arcutis Biotherapeutics, Inc. →